View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
SSA RIN: 0960-AG57 Publication ID: Fall 2009 
Title: Revised Medical Criteria for Evaluating Malignant Neoplastic Diseases (3429F) 
Abstract: Sections 13.00 and 113.00, Malignant Neoplastic Diseases, of appendix 1 to subpart P of part 404 of our regulations describe malignant neoplastic diseases that are considered severe enough to prevent a person from doing any gainful activity, or that cause marked and severe functional limitations for a child claiming SSI payments under title XVI. We are revising these sections to ensure that the medical evaluation criteria are up-to-date and consistent with the latest advances in medical knowledge and treatment. 
Agency: Social Security Administration(SSA)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Completed Actions 
Major: No  Unfunded Mandates: No 
CFR Citation: 20 CFR 404.1500, app 1   
Legal Authority: 42 USC 402    42 USC 405(a)    42 USC 405(b)    42 USC 405(d) to 42 USC 405(h)    42 USC 416(i)    42 USC 421(a)    42 USC 421(i)    42 USC 422(c)    42 USC 423    42 USC 425    42 USC 902(a)(5)   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  04/28/2008  73 FR 22871   
NPRM Comment Period End  06/27/2008    
Final Action  10/06/2009  74 FR 51229   
Final Action Effective  11/05/2009    
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Cheryl A. Williams
Director
Social Security Administration
Office of Medical Policy, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 965-1020
Email: cheryl.a.williams@ssa.gov

Rosemarie Greenwald
Social Insurance Specialist, Regulations Writer
Social Security Administration
Office of Regulations, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 966-7813